Dr Janice Tan Ser Huey

Dr. Janice Tan Ser Huey obtained her MBChB from the University of Manchester (UK) in 2012 and completed her Core Medical Training with the NHS (UK), obtaining her MRCP (UK) in 2015. She subsequently underwent six years of training in Radiation Oncology at the National Cancer Centre Singapore and qualified as a Fellow in Clinical Oncology from the Royal College of Radiologists (UK) and attained her Specialist Accreditation in Radiation Oncology in 2025.

She sub-specialises in the treatment of patients with genitourinary and head and neck cancers. Her research interests are in precision and translational oncology in nasopharyngeal and prostate cancers where she has contributed to multiple international peer-reviewed journals.

• FRCR (Clinical Oncology) (UK) 
• MRCP (UK) 
• MBChB (Manchester, UK)

• Associate Consultant, Division of Radiation Oncology, NCCS 
• Fellow (Clinical Oncology), Royal College of Radiologists (UK)

• NCCS Research Publication Award 2024 
• Service with the Heart Award 2019

• Yeo ELL, Hong BH, SH Tay, Neo JL, Ong EHW, Chow WM, Tan KM, Low KP, Sim AYL, Lu T, Zhang X, Huang L, Tan JSH, et al. Tumor immune microenvironment delineates progression trajectories of distinct nasopharyngeal carcinoma phenotypes. Cell Reports Medicine Jun 2025;6(5):102143
• Tan JSH, Tay TKY, Ong EHW et al. Combinatorial hypofractionated radiotherapy and pembrolizumab in anaplastic thyroid cancer. Eur Thyroid J Jan 2024 1;13(1): e230144
• Neo JL, Yip PL, Ong EHW, Miao JJ, Chow WM, Wee JTS, Fong KW, Soong YL, Tan TWK, Tan JSH, et al. Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma. Oral Oncol. Jan 2024: 148:1066555. 
• Tan JSH, Teh JYH, Tan LLY, et al. Efficacy, toxicity, and quality-of-life outcomes of ultrahypofraction-ated radiotherapy in patients with localized prostate cancer: A single-arm phase 2 trial from Asia. Asia Pacific Journal of Clinical Oncology Dec 2021; 18(5):e346-355  
• Tan JSH, Goh CXY, Li YQ et al, 68-Ga prostate-specific membrane antigen-PET as a diagnostic and clinical decision-making tool in biochemical recurrences post-radical prostatectomy. Cancer Biol Med Feb 2019; 16(1): 157-66. PMID: 31119056 
• Li YQ, Tan JSH, Wee JTS, Chua MLK. Adaptive radiotherapy in the treatment of head and neck can-cers: fact or fallacy to improve therapeutic ratio. Cancer Radiotherapie, May 2018;22(3)287-295.PMID: 29699832 
• Tan JSH, Lin X, Chua MLK, Lam PY, Soo KC, Chua MLK. Exploiting molecular genomics in precision radiation oncology: a marriage of biological and physical precision. Chin Clin Oncol. Sep 2017;6(Suppl 2):S19. doi: 10.21037/cco.2017.06.31. 
• Frinton E, Tong D, Tan JSH, Read G, Kumar V, Kennedy S, Lim C, Board R. Metastatic melanoma: prognostic factors and survival in patients with brain metastases. J Neurooncol 2017 Dec;135(3):507-512. doi: 10.1007/s11060-017-2591-9. Epub Aug 2017 17. PMID:28819707